Additionally, unexpected hypoglycemia, severe gastrointestinal symptoms beyond typical tirzepatide effects, or allergic reactions may indicate formulation problems
however, possible side effects may include: Local irritation at the injection site
The pharmacokinetics suit a once-weekly rhythm, with an approximate six-day half-life confirmed in the early phase 1b work
Studies in structured and preclinical models have shown that changes in this pathway can influence lipid metabolism indicators, mitochondrial activity markers, and energy balance signals under standardized conditions
Detailed and structured history taking that captures symptom onset, severity, cyclical patterns, and associated features such as gastrointestinal or urinary symptoms has been shown to improve diagnostic suspicion